Clinical Trial

A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

Completed Phase 3
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the efficacy and safety of HRS9531 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors compared to Semaglutide QW for 36 weeks and 52 weeks.
Protocol Amendment History 3 changes
critical Trial completed 2026-07-31
notable Primary completion moved earlier: 2026-09-30 -> 2026-07-18 2026-07-31
minor Completion moved earlier: 2026-09-30 -> 2026-07-18 2026-07-31
Trial Details
NCT Number NCT06649344
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Type 2 Diabetes
Enrollment 884 participants
Start Date 2024-10-31
Primary Completion 2026-07-18 (estimated)
Study Completion 2026-07-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-30